FOS and small cell lung carcinoma: Aberrant electrical activity drives SCLC malignancy via the calcium-dependent CREB/FOS pathway, providing a rationale for employing nAChR inhibitors (e.g., varenicline), calcium signaling modulators, or sodium channel blockers (55).